CME vs StoneX
CME and SNEX side by side, both in security & commodity brokers, dealers, exchanges & services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CME and SNEX compare
CME is the larger company, worth 17 times as much as StoneX ($109B against $6.4B).
On earnings, StoneX is cheaper: it trades at 12.5× trailing earnings, against 25.7× for CME.
StoneX grew revenue faster over the last twelve months (20.6% versus 5.1% for CME).
CME pays a dividend yielding 3.7%; StoneX does not pay one.
StoneX scores higher on the StockData Score (17 against 9 for CME), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CME | SNEX |
|---|---|---|
| Size and price | ||
| Market cap | $109B | $6.4B |
| Share price | $303.14 | $52.83 |
| Change, 1 year | 15.9% | 27.5% |
| Change, 5 years | 36.7% | 273% |
| Beta (5Y) | 0.36 | 0.73 |
| Employees | 3,875 | 5,400 |
| StockData Score | ||
| Total score | 9 | 17 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 4 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 5 | 5 |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/E | 25.7× | 12.5× (better) |
| P/S | 16.1× | 0.0× (better) |
| P/B | 4.1× | 2.2× (better) |
| EV/EBITDA | 24.2× | 5.3× (better) |
| P/FCF | 25.9× | 1.7× (better) |
| PEG | 1.75 | 1.28 (better) |
| FCF yield | 3.9% | 59.4% (better) |
| Fair value | $250.81 | $87.44 |
| Margin of safety | −20.9% | 39.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.1% | 20.6% (better) |
| Revenue growth, 5Y average | 6.0% | 19.6% (better) |
| Net income growth (TTM) | – | 77.5% |
| EPS growth (TTM) | 14.1% | 60.3% (better) |
| EPS growth, 5Y average | 13.7% (better) | 9.0% |
| Profitability | ||
| Gross margin | – | 3.6% |
| Operating margin | 65.1% | – |
| Net margin | – | 0.33% |
| FCF margin | 62.2% (better) | 2.4% |
| Return on equity | – | 21.9% |
| Return on invested capital | 13.5% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.02 | – |
| Altman Z-score | 0.56 | 3.05 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 3.7% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −3.3% | – |
| Shareholder yield | 3.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 89.5% | 83.5% |
| Held by insiders | 0.34% | 9.1% |
| Insider net buying, 12 months | −$30.4M (better) | −$173M |
| Superinvestors holding | 5 | – |
| Short interest, % of float | 1.5% | 4.4% |
Go deeper
- CME stock overview
- CME income statement
- CME valuation and score
- SNEX stock overview
- SNEX income statement
- SNEX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.